Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 131.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 131.85% | |||
| Cost of Revenue | 23.84% | -74.44% | |||
| Gross Profit | -907.14% | 102.04% | |||
| SG&A Expenses | 36.89% | -0.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.30% | -44.54% | |||
| Operating Income | -95.30% | 75.63% | |||
| Income Before Tax | -46.27% | 63.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -46.27% | 63.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.27% | 63.26% | |||
| EBIT | -95.30% | 75.63% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -43.48% | 65.41% | |||
| Normalized Basic EPS | -44.83% | 65.06% | |||
| EPS Diluted | -43.48% | 65.41% | |||
| Normalized Diluted EPS | -44.83% | 65.06% | |||
| Average Basic Shares Outstanding | 0.81% | 6.86% | |||
| Average Diluted Shares Outstanding | 0.81% | 6.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||